孟德尔随机化研究：体重指数与心力衰竭临床结局及死亡率的关联
该研究利用两样本孟德尔随机化方法，纳入22个队列共50,636例欧洲裔心衰患者，评估基因预测的BMI与临床结局的关联。结果显示，BMI每增加1个标准差（4.8 kg/m²），全因死亡风险增加21%，心血管死亡或心衰住院复合终点风险增加29%，且该关联在LVEF≤40%和>40%亚组中均存在。研究支持在心衰各射血分数谱系中考虑体重管理策略。
要点
- 基因预测BMI每增4.8 kg/m²，全因死亡HR 1.21，复合终点HR 1.29。
- 关联在LVEF≤40%与>40%亚组中方向一致，但部分置信区间跨1。
- 结果提示减重或可改善心衰结局，但需随机对照试验进一步证实。
核心结论
- 在心衰患者中，较高BMI与全因死亡及心血管死亡或心衰住院复合终点风险增加相关，支持跨射血分数谱系实施体重管理策略。
研究设计与样本
- 两样本孟德尔随机化研究，以全基因组显著BMI相关位点作为工具变量。
- 结果数据来自心衰患者时间-事件临床结局的GWAS，共22个队列50,636例欧洲裔个体。
主要发现
- 平均BMI 29.2±5.8 kg/m²，中位随访27.0个月。
- 全因死亡发生11,454例（23%），复合终点11,360例（22%）。
- 基因预测BMI每增加1个标准差（4.8 kg/m²），全因死亡HR 1.21（95%CI 1.13-1.29，P=9×10⁻⁸）。
- 复合终点HR 1.29（95%CI 1.20-1.38，P=8×10⁻¹³）。
- LVEF≤40%亚组：全因死亡HR 1.16（95%CI 0.99-1.37），复合终点HR 1.30（95%CI 1.15-1.48）。
关键数值与推荐
- BMI每标准差（4.8 kg/m²）增加，全因死亡风险增加21%，复合终点风险增加29%。
- LVEF≤40%亚组复合终点风险增加30%，LVEF>40%亚组增加57%。
临床怎么用
- 心衰患者无论射血分数高低，均应将体重管理纳入综合治疗策略。
- 该研究为观察性证据，临床决策需结合患者具体情况及后续干预试验结果。
局限性
- 仅纳入欧洲裔人群，外推至其他种族需谨慎。
- 孟德尔随机化评估的是基因预测BMI的长期效应，与短期减重干预效果可能存在差异。
- 部分亚组置信区间较宽，精确估计受限。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
原文
BACKGROUND: Excess adiposity, most commonly indexed through body mass index (BMI), is strongly associated with the development of heart failure (HF). Weight loss therapies improve outcomes in patients with obesity and HF with preserved left ventricular ejection fraction (LVEF), but their effects in HF with reduced LVEF remain unclear. OBJECTIVES: The aim of this work is to determine whether higher BMI is associated with adverse clinical outcomes in patients with HF and whether there is effect modification by LVEF subgroup. METHODS: Two-sample Mendelian randomization (MR) was used, with genome-wide significant loci associated with BMI as instrumental variables and outcome data from a genome-wide association study (GWAS) of time-to-event clinical outcomes in patients with HF. A total of 50,636 individuals of European ancestry with established HF from 22 cohorts were included in the genetic analysis: 12 HF trials, 1 prospective case-cohort study, 9 cohorts nested within non-HF cardiovascular trials, and 1 population-based cohort derived from the UK Biobank. The exposure was genetically predicted BMI and the outcome measures were all-cause mortality and a composite of cardiovascular mortality or HF hospitalization. Genetic associations for the outcomes were derived from our GWAS and MR was used to estimate the unbiased association of genetically predicted BMI with these clinical outcomes. RESULTS: The mean BMI was 29.2 ± 5.8 kg/m2. Over a median follow-up of 27.0 months, all-cause mortality occurred in 11,454 patients (23%), and 11,360 participants (22%) experienced the composite endpoint. Genetically predicted BMI was associated with an increased rate of both all-cause mortality (HR per SD [4.8 BMI units] 1.21; 95% CI: 1.13-1.29; P = 9 × 10-8) and the composite outcome (HR 1.29; 95% CI: 1.20-1.38; P = 8 × 10-13). Associations were consistent across LVEF ≤40% and >40%: for all-cause mortality, HR: 1.16 (95% CI: 0.99-1.37) and 1.20 (95% CI: 0.94-1.53); and for the composite outcome, HR: 1.30 (95% CI: 1.15-1.48) and 1.57 (95% CI: 1.29-1.91), respectively. CONCLUSIONS: Among patients with HF, higher BMI was associated with increased all-cause mortality and cardiovascular death or HF hospitalization, supporting the potential role of weight-management strategies across the ejection fraction spectrum.
引用
- Sunderland, Asselin, Henry, et al. Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study. J Am Coll Cardiol. 2026. PMID: 42017882. doi:10.1016/j.jacc.2026.02.5093
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。